Pacritinib and concurrent azole antifungal therapy is deliverable in patients with hematologic malignancies.

This is the first clinical experience describing concurrent pacritinib and azole antifungals. Our experience shows that in the setting where this interaction cannot be avoided, concurrent administration is feasible with close monitoring and possible empiric dose reductions in select patients.